paclitaxel,olaparib,bevacizumab,carboplatin,durvalumab
roche,merck,astrazeneca
['olaparib', 'durva', 'duo-o', 'sting study', 'ovarian']
duo-o- interesting study looking at addition of durvalumab and olaparib to chemo+bev in upfront/maintenance treatment of advanced ovarian cancer. pfs results are compelling but we need arm 2 comparison data to see if the pfs benefit is explained by olaparib alone. #asco23 
Gyn Onc fellow at @MDAndersonNews via @ColumbiaOBGYN and @UVA x2 | College Basketball Enthusiast (Go Hoos!) | Married to @MrrSandman | All views are my own